Price movement over the last 24 hours
ARK Autonomous Technology & Robotics ETF vs Danaher Corporation — how do they compare? ARK Autonomous Technology & Robotics ETF trades at $123.27, while Danaher Corporation trades at $199.08 (market cap $140.88B). The key difference: Danaher Corporation pays a 0.8% dividend while ARK Autonomous Technology & Robotics ETF pays none, and ARK Autonomous Technology & Robotics ETF is trading nearer its 52-week high, Danaher Corporation nearer its low. Which is the better fit depends on your goals.
| ARKQ | DHR | |
|---|---|---|
Sector | Sector/Thematic | Health |
52-Week High | $143.82 | $242.05 |
52-Week Low | $91.86 | $161.91 |
Market Cap | — | $140.88B |
Enterprise Value | — | $153.66B |
Dividend Yield | — | 0.8% |
Signals from Pluang's Aura AI — not financial advice
ARKQ trades at $123.99, down 0.57% with a bearish technical signal from moving averages. The ETF focuses on autonomous technology and robotics, benefiting from AI momentum with 57% gains since Q1 2026. Support levels cluster around $122-124 while resistance sits at $126-128. Recent news highlights China's EV targets and humanoid robotics growth projections reaching $200 billion by 2035.
The ETF shows strong momentum in AI and robotics themes but carries premium valuations with a 36x P/E ratio. Key risks include sector concentration and dependency on technological adoption rates. Institutional interest remains strong with $2.7 billion in assets, though technical indicators suggest near-term consolidation pressure.
Danaher (DHR) trades at $199.05, up 1.57% today, with strong technical momentum as price approaches resistance at $200. The company demonstrates consistent earnings beats with Q1 2026 EPS of $2.06 exceeding expectations of $1.94, though revenue growth remains modest at 2.9% year-over-year. Recent developments include the Masimo acquisition approval and new product launches in the biotechnology segment, supporting positive analyst sentiment.
DHR presents a mixed outlook with strong analyst support (69% buy ratings) and a $214.73 consensus target offering 7.9% upside, but faces risks from elevated valuation (P/E 38.58) and slowing profit margins. The stock's near-term direction will depend on Q2 2026 earnings delivery and biotechnology segment performance amid competitive pressures.
Trailing returns across standard periods
ARKQ is an actively managed ETF that invests in autonomous technology and robotics. It focuses on disruptive innovations like autonomous mobility, electric vehicles, 3D printing, and energy storage, with holdings such as Tesla and Teradyne.
Read more on ARKQ →In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Through a series of mergers, acquisitions, and divestitures, including the Fortive separation in 2016, Danaher now focuses primarily on manufacturing scientific instruments and consumables in three segments: life sciences, diagnostics, and environmental and applied solutions. In late 2019, Danaher separated from its dental business through an initial public offering process, and in early 2020, it acquired GE's Biopharma business, now called Cytiva, which added to its life sciences segment.
Read more on DHR →